Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential

Source Motley_fool

Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 19, 2025. The video was published on March 26, 2025.

Should you invest $1,000 in Neurocrine Biosciences right now?

Before you buy stock in Neurocrine Biosciences, consider this:

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Neurocrine Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $739,720!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of March 24, 2025

Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia Earnings in Focus as Asian Markets Cautiously Await Key Economic DataAsian stock markets are on edge as investors eye Nvidia’s upcoming earnings report amid speculation surrounding interest rates and the broader implications for the AI stock rally and U.S. economic indicators.
Author  Mitrade
Nov 17, 2025
Asian stock markets are on edge as investors eye Nvidia’s upcoming earnings report amid speculation surrounding interest rates and the broader implications for the AI stock rally and U.S. economic indicators.
placeholder
Solana Price Outlook: What To Expect From SOL In April 2026Solana (SOL) price enters April 2026 under pressure. March is closing at roughly -0.88%, extending a red streak that now stretches six consecutive months since October 2025.A head-and-shoulders breakd
Author  Beincrypto
Mar 31, Tue
Solana (SOL) price enters April 2026 under pressure. March is closing at roughly -0.88%, extending a red streak that now stretches six consecutive months since October 2025.A head-and-shoulders breakd
placeholder
Why are prediction market traders suddenly bearish on Nvidia's stock?Nvidia (NASDAQ: NVDA) stock is still green for 2026, but the trade no longer looks clean from the company that outperformed every other company and country in 2024 and 2025. NND is up about 12% this year, yet they have slipped roughly 3% over the past month. The gap with the rest of the chip...
Author  Cryptopolitan
Jun 23, Tue
Nvidia (NASDAQ: NVDA) stock is still green for 2026, but the trade no longer looks clean from the company that outperformed every other company and country in 2024 and 2025. NND is up about 12% this year, yet they have slipped roughly 3% over the past month. The gap with the rest of the chip...
placeholder
OpenAI Could Reportedly Delay IPO After SpaceX ScareOpenAI executives are reportedly urging caution on its IPO timeline after SpaceX’s turbulent public debut, highlighting risks in mega-AI listings.The development comes as Polymarket traders price roug
Author  Beincrypto
22 hours ago
OpenAI executives are reportedly urging caution on its IPO timeline after SpaceX’s turbulent public debut, highlighting risks in mega-AI listings.The development comes as Polymarket traders price roug
placeholder
OpenAI tilts toward 2027 IPO as Anthropic prepares to list firstOpenAI is leaning toward postponing its initial public offering until 2027, per a New York Times report on June 25 citing people involved in the company’s internal deliberations. The shift represents a reversal from the late-2026 timeline OpenAI has signaled since January, with CEO Sam Altman rejecting any valuation below $1 trillion and CFO Sarah...
Author  Cryptopolitan
22 hours ago
OpenAI is leaning toward postponing its initial public offering until 2027, per a New York Times report on June 25 citing people involved in the company’s internal deliberations. The shift represents a reversal from the late-2026 timeline OpenAI has signaled since January, with CEO Sam Altman rejecting any valuation below $1 trillion and CFO Sarah...
goTop
quote